Why is Alkem Laboratories Ltd ?
1
High Management Efficiency with a high ROE of 15.73%
2
Company has a low Debt to Equity ratio (avg) at 0.01 times
3
Poor long term growth as Operating profit has grown by an annual rate 8.97% of over the last 5 years
4
Flat results in Sep 26
- PAT(Q) At Rs 651.96 cr has Fallen at -14.8%
- CASH AND CASH EQUIVALENTS(HY) Lowest at Rs 617.53 cr
- INTEREST(Q) Highest at Rs 57.67 cr
5
Stock is technically in a Bearish range
- The technical trend has deteriorated from Mildly Bearish on 20-Nov-26
- The stocks MACD and KST technical factors are also Bearish
6
With ROE of 14.6, it has a Attractive valuation with a 4.2 Price to Book Value
- The stock is trading at a fair value compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -9.36%, its profits have fallen by -7.7%
7
High Institutional Holdings at 33.15%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
8
Below par performance in long term as well as near term
- Along with generating -9.36% returns in the last 1 year, the stock has also underperformed BSE500 in the last 3 years, 1 year and 3 months
How much should you hold?
- Overall Portfolio exposure to Alkem Lab should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Alkem Lab for you?
Low Risk, Low Return
Absolute
Risk Adjusted
Volatility
Alkem Lab
-9.36%
-0.39
24.24%
Sensex
-2.0%
-0.13
14.98%
Quality key factors
Factor
Value
Sales Growth (5y)
9.26%
EBIT Growth (5y)
8.97%
EBIT to Interest (avg)
16.46
Debt to EBITDA (avg)
0.82
Net Debt to Equity (avg)
0.06
Sales to Capital Employed (avg)
0.99
Tax Ratio
29.61%
Dividend Payout Ratio
24.84%
Pledged Shares
0
Institutional Holding
33.15%
ROCE (avg)
19.05%
ROE (avg)
15.73%
Valuation Key Factors 
Factor
Value
P/E Ratio
28
Industry P/E
40
Price to Book Value
4.16
EV to EBIT
23.20
EV to EBITDA
19.96
EV to Capital Employed
3.99
EV to Sales
4.00
PEG Ratio
NA
Dividend Yield
1.03%
ROCE (Latest)
17.19%
ROE (Latest)
14.59%
Loading Valuation Snapshot...
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
Technical Movement
4What is working for the Company
NET SALES(Q)
Highest at Rs 4,551.99 cr
PBDIT(Q)
Highest at Rs 1,025.19 cr.
PBT LESS OI(Q)
Highest at Rs 830.44 cr.
-9What is not working for the Company
PAT(Q)
At Rs 651.96 cr has Fallen at -14.8%
CASH AND CASH EQUIVALENTS(HY)
Lowest at Rs 617.53 cr
INTEREST(Q)
Highest at Rs 57.67 cr
Loading Valuation Snapshot...
Here's what is working for Alkem Lab
Net Sales - Quarterly
Highest at Rs 4,551.99 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 1,025.19 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 830.44 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Here's what is not working for Alkem Lab
Profit After Tax (PAT) - Quarterly
At Rs 651.96 cr has Fallen at -14.8%
Year on Year (YoY)MOJO Watch
Near term PAT trend is very negative
PAT (Rs Cr)
Interest - Quarterly
Highest at Rs 57.67 cr
in the last five quarters and Increased by 23.70 % (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (Rs cr)
Cash and Cash Equivalents - Half Yearly
Lowest at Rs 617.53 cr
in the last six half yearly periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents